Overview of key results for the second half of the 2023 financial year
• 14% growth in operating revenue to $890.5 million, 12% growth in constant currency.
• Net profit after tax of $154.4 million, a decline of 0.5% or 3% in constant currency.
• 9% growth in Hospital operating revenue to $584.8 million, 7% growth in constant currency.
• 13% constant currency revenue growth for new applications consumables; i.e. products used in noninvasive ventilation, Optiflow nasal high flow therapy and surgical applications, accounting for 72% of Hospital consumables revenue.
• 25% growth in Homecare operating revenue to $303.9 million, 22% growth in constant currency.
• 28% growth in OSA masks revenue, or 24% growth in constant currency.
Overview of key results for the 2023 financial year
• 34% decline in net profit after tax to $250.3 million, 39% decline in constant currency.
• 6% decline in operating revenue to $1.58 billion, 9% decline in constant currency.
• 15% decline in Hospital operating revenue to $1.02 billion, 18% decline in constant currency.
• 6% constant currency revenue decline for new applications consumables.
• 18% growth in Homecare operating revenue to $553.8 million, 13% growth in constant currency.
• Investment in R&D was 11% of revenue, or $174.3 million.
• 2% increase in final dividend to 23.0 cps (2022: 22.5 cps).
• 3% increase in total dividends for the financial year to 40.5 cps (2022: 39.5 cps).
Single digit revenue growth expected ….. trading on a PE of 60 ….hmmmmm
For longterm holders it will only rise over time and this is just a short term blip, but for traders a song by Kaleo comes to mind. “Way down we go” of course I could be wrong….
Bookmarks